Law No. 17 of 2026 created a longevity regulator that sits beside the DHA, and some of what your wellness or regenerative lines already do may now fall under it.
Law No. 17 of 2026, issued 10 June, created the Dubai Longevity Authority to license the longevity chain. Detailed rules are still to come.
What a board member needs before the next meeting on this.
- A new licence line opened beside the DHA. The DLA regulates the longevity value chain end to end; part of what your wellness lines already do may now fall under it.
- The rules are announced, not published. The perimeter exists; the detailed licensing framework does not yet — and that gap is the planning window.
- Map each service line against the value chain. Some lines are clearly DHA, some clearly longevity; the ambiguous middle is where your risk concentrates.
- For investors, attribution is now a diligence line. A DHA-priced regenerative asset may be re-scoped under a stricter DLA framework, moving both timeline and multiple.
Dubai just drew a new licensing line, and your clinic may sit on the wrong side of it
On 10 June 2026, Sheikh Mohammed bin Rashid issued Law No. 17 of 2026 establishing the Dubai Longevity Authority. It is a distinct regulator that sits beside the DHA rather than inside it, and its remit runs the longevity value chain end to end: research and development, clinical trials, manufacturing, delivery, and patient-facing clinics. If your group runs anti-ageing, IV-wellness, regenerative, or cell-therapy lines, the question is no longer only whether you hold a DHA facility licence. It is whether part of what you already do now falls under the DLA.
One point of housekeeping before the substance. Some early coverage misnamed the body. Gulf News first ran it as the Dubai Health Sustainability Authority and others as the Dubai Authority for Healthy Longevity. The law names it the Dubai Longevity Authority and always did, so read the variants as press errors rather than as separate authorities.
The structure signals how serious this is
Leadership was set quickly. Decree No. 14 of 2026 named Sheikh Hamdan bin Mohammed as President, and Decree No. 15 of 2026 named Helal Saeed Almarri as Chairman. The DLA is mandated to coordinate with the DHA, Dubai Health, Dubai Municipality, and the Dubai Future Foundation, which tells you where the seams will run. A longevity clinic touches clinical licensing, public-health oversight, municipal wellness rules, and an innovation agenda at the same time, and the new authority is being positioned to sit across all of them rather than defer to any one.
The rules are announced, not published
The law creates the perimeter. The detailed licensing framework that will decide which services need a DLA permit, on what evidence, and on what timeline, has not yet been released. That gap is not a reason to wait. It is the planning window, and it favours operators who use it to get ahead of the definitions rather than react to them once they are fixed. When a regulator describes itself as science-led and risk-proportionate, the operators who prepare an evidence file early tend to fare better than those who discover the standard at inspection.
Map your service lines against the value chain now
Take each thing you offer and place it against the language of the law. Some services sit clearly under the DHA and are unlikely to move. Some read plainly as longevity and will almost certainly attract DLA oversight. A meaningful set will be ambiguous, and that ambiguous middle is where your regulatory and commercial risk concentrates. Knowing which bucket each line falls into is the difference between shaping your positioning while the rules are still forming and being reclassified after you have built the business case on the old assumption.
For investors, regulatory attribution is now a diligence line with real value attached
A regenerative or cell-therapy asset priced on a DHA basis may be re-scoped under a stricter DLA framework, and the licensing path drives both the timeline to revenue and the multiple you can defend. Any thesis in Dubai longevity or wellness written after 10 June 2026 that does not ask which authority governs the target's core service lines is carrying an unpriced risk. The same logic runs the other way for the well-prepared: a clean, DLA-anticipating regulatory position is becoming a value driver in a sector Dubai has openly decided to lead.
The authorities Dubai stands up rarely stay quiet for long, and the interval before the licensing rules land is short. Operators and investors who treat this window as diligence time, not dead time, will set their positioning before the framework hardens around them. The early movers in a new licensing regime often help shape how the ambiguous categories get read, simply by being the first credible files an authority reviews. That is worth more than the cost of preparing early, and it is only available while the rules are still being written.
Four questions while the rules are still forming
- Which of our service lines read plainly as longevity, which as DHA, and which are ambiguous?
- For an asset in diligence, which authority governs its core service lines?
- What evidence file would a science-led DLA reviewer expect to see?
- Are we positioned to shape the ambiguous categories, or reacting after they harden?
Avior helps longevity, wellness, and regenerative operators and their investors read where each service line sits across the DHA and the new DLA, and what that means for licensing and for value. Our market access and regulatory team is built for exactly this kind of perimeter question.